Skip to main content
. 2016 Mar 21;34(20):2359–2365. doi: 10.1200/JCO.2015.63.1960

Fig 2.

Fig 2.

Median time to (A and B) first progression and (C and D) 2-year overall survival by risk group among patients with ER-positive (n = 85) and ER-positive/HER2-negative (n = 69) de novo stage IV breast cancer. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; RS, Recurrence Score.